YANNIS MOREL

About YANNIS MOREL

Yannis Morel, PhD, is currently Chief Operating Officer at Innate Pharma, a French listed biopharmaceutical company focused on immuno-oncology. He is also a member of the Executive Board. His career is notable for its strong internal progression: he joined Innate Pharma in December 2001 and first worked in R&D, initially as a scientist in the immunology team, then as a team manager, and later as the person responsible for research programs. In 2007, he moved into business development, where he helped shape the company’s partnering and portfolio strategy. In January 2024, his remit was expanded to Chief Operating Officer, giving him broader operational responsibility, including oversight of research and early development in coordination with the company’s scientific leadership. Morel’s profile combines scientific depth with strategic and transactional expertise, a valuable combination in the biotechnology sector. Over time, he has become a central executive in Innate Pharma’s efforts to advance its pipeline and convert scientific assets into value-creating collaborations. His role has been closely associated with the company’s ability to engage with major pharmaceutical partners and to structure agreements that support development while preserving strategic optionality. This makes him particularly important in a business model where external partnerships, scientific differentiation, and disciplined capital allocation are all critical. He holds a PhD in molecular physical chemistry from Aix-Marseille University and is an alumnus of École Normale Supérieure de Paris-Saclay (formerly ENS Cachan). That academic background, combined with more than two decades at Innate Pharma, gives him deep institutional knowledge and strong credibility both internally and in the broader biotech ecosystem. As COO, he represents the operational continuity and scientific rigor behind Innate Pharma’s executive leadership.